Last updated: September 7, 2026
Flutemetamol F-18, marketed as Vizamyl by GE HealthCare, is an FDA-approved amyloid PET radiopharmaceutical used to estimate beta-amyloid neuritic plaque density in adults with cognitive impairment. Its commercial outlook depends less on conventional prescription volume than on PET-site access, Medicare and commercial reimbursement, radiopharmacy logistics, and demand generated by Alzheimer’s disease disease-modifying therapies.
Vizamyl has a durable clinical role but a limited public financial profile. GE HealthCare does not separately report Vizamyl revenue, margins, or unit volume. Growth is likely to be gradual rather than explosive because amyloid PET remains capacity-constrained, interpretation requires specialized imaging expertise, and competing tracers are available.
What is flutemetamol F-18 and what is Vizamyl used for?
Vizamyl is an intravenous fluorine-18-labeled PET imaging agent. It binds to beta-amyloid plaques in the brain, allowing PET imaging to estimate plaque density.
The FDA approved Vizamyl on October 25, 2013, for adults with cognitive impairment undergoing evaluation for Alzheimer’s disease and other causes of cognitive decline. A positive scan indicates moderate to frequent amyloid neuritic plaques, while a negative scan indicates sparse or no plaques. The label states that the scan is an adjunct to other diagnostic evaluations and does not independently establish a diagnosis of Alzheimer’s disease or another cognitive disorder (FDA, 2013).
| Product attribute |
Vizamyl profile |
| Active imaging agent |
Flutemetamol F-18 injection |
| Manufacturer |
GE HealthCare |
| FDA approval |
October 25, 2013 |
| Administration |
Intravenous |
| Imaging modality |
PET |
| Primary use |
Estimation of beta-amyloid neuritic plaque density |
| Target population |
Adults with cognitive impairment |
| Fluorine-18 physical half-life |
Approximately 110 minutes |
| Typical imaging window |
Approximately 90 to 110 minutes after injection |
| Commercial form |
Single-use radiopharmaceutical dose |
| Therapeutic activity |
None; diagnostic imaging only |
The short half-life creates a different commercial model from oral drugs. Vizamyl must be produced, quality-tested, shipped, administered, and scanned within a narrow operating window. The product is therefore sold through a radiopharmacy and nuclear medicine infrastructure rather than through retail pharmacies.
How large is the flutemetamol F-18 market?
The public market size for Vizamyl is not separately disclosed. Its addressable market is a subset of the broader Alzheimer’s diagnostic imaging market.
Demand is determined by four factors:
- The number of patients undergoing specialist cognitive evaluation.
- The number of PET-capable imaging centers.
- Payer willingness to reimburse amyloid PET.
- The need to confirm amyloid pathology before prescribing or monitoring anti-amyloid therapies.
The launch market was limited because amyloid PET was primarily used in complex or uncertain cases. The commercial environment changed after approval of anti-amyloid antibodies, including lecanemab and donanemab. These therapies require evidence of amyloid pathology before treatment, increasing the potential role of amyloid PET in diagnostic pathways.
The increase in potential demand does not translate directly into equivalent Vizamyl revenue. Amyloid status can also be evaluated through cerebrospinal fluid testing and, increasingly, blood-based biomarkers. Some patients may receive treatment based on non-PET testing, while others may lack access to PET or face reimbursement restrictions.
What is the financial trajectory for Vizamyl?
GE HealthCare does not report Vizamyl as a standalone revenue line. The product is included within the company’s broader Pharmaceutical Diagnostics activities, and public filings do not identify sales, gross profit, market share, or operating income attributable specifically to flutemetamol F-18 (GE HealthCare Technologies Inc., 2024).
The financial trajectory can therefore be assessed through market drivers rather than reported product revenue.
2013-2019: specialist diagnostic adoption
Vizamyl entered a market dominated by limited specialist use. Adoption was constrained by:
- Restricted reimbursement for amyloid PET.
- Limited PET infrastructure outside major medical centers.
- Diagnostic uncertainty about how a positive scan changed treatment.
- Competition from Eli Lilly’s Amyvid and Piramal Imaging’s Neuraceq.
- Operational complexity caused by the short half-life of fluorine-18.
During this period, Vizamyl’s commercial value was linked to neurology centers, academic hospitals, and specialized nuclear medicine practices.
2020-2022: infrastructure and reimbursement expansion
The Alzheimer’s diagnostic market benefited from greater clinical interest in biomarker-confirmed disease. Radiopharmacy networks and PET capacity expanded in selected markets, although geographic access remained uneven.
The COVID-19 pandemic disrupted elective imaging volumes in 2020 and part of 2021. Recovery depended on hospital procedure volumes, staffing, and local reimbursement.
2023 onward: anti-amyloid therapy pull-through
FDA approvals of lecanemab in 2023 and donanemab in 2024 increased the economic value of confirming amyloid pathology. The labels for these therapies require evidence of amyloid beta pathology before treatment. Amyloid PET is one pathway for obtaining that evidence, although cerebrospinal fluid and blood-based tests may compete for the same diagnostic decision.
The current trajectory is best described as moderate market expansion with uncertain product-level capture. The total addressable diagnostic pool is rising, but Vizamyl must compete for each scan against other approved tracers and non-PET tests.
Which companies compete with flutemetamol F-18?
Vizamyl competes with two principal FDA-approved amyloid PET tracers and with non-PET diagnostic methods.
| Product |
Active ingredient |
Company or commercial sponsor |
FDA approval |
Competitive position |
| Vizamyl |
Flutemetamol F-18 |
GE HealthCare |
2013 |
Established PET tracer with GE radiopharmacy infrastructure |
| Amyvid |
Florbetapir F-18 |
Eli Lilly |
2012 |
First FDA-approved amyloid PET agent; established clinical awareness |
| Neuraceq |
Florbetaben F-18 |
Life Molecular Imaging, formerly Piramal Imaging |
2014 |
Direct amyloid PET competitor |
| Blood-based biomarkers |
Various analytes |
Multiple developers |
Evolving |
Potential lower-cost, higher-access alternative |
| CSF testing |
Amyloid and tau biomarkers |
Hospital and laboratory providers |
Established diagnostic method |
Competes where lumbar puncture is acceptable |
Tracer selection is influenced by local supply, radiopharmacy relationships, physician familiarity, image quality, interpretation training, payer policies, and contractual pricing. The products have the same broad clinical purpose, so differentiation is primarily operational and commercial rather than based on a materially different therapeutic effect.
What regulatory status does Vizamyl have?
Vizamyl is an FDA-approved diagnostic radiopharmaceutical. It is not a biologic and has no biosimilar pathway.
Its label includes important interpretation limitations. A positive scan does not establish Alzheimer’s disease because amyloid deposition can occur in other neurologic conditions and in cognitively normal older adults. A negative scan reduces the likelihood that cognitive impairment is caused by Alzheimer’s disease at the time of imaging, but it does not exclude other causes of cognitive decline (FDA, 2013).
The product is subject to radiopharmaceutical manufacturing, sterility, quality-control, labeling, and distribution requirements. Manufacturing deviations or supply interruptions can affect commercial performance more quickly than for conventional drugs because doses cannot be stockpiled for long periods.
What reimbursement factors affect flutemetamol F-18 sales?
Reimbursement is one of the main constraints on Vizamyl utilization.
Medicare historically limited amyloid PET coverage through a national coverage policy requiring coverage with evidence development. Subsequent coverage decisions and local payer policies have created a mixed reimbursement environment. Coverage can depend on the clinical indication, site of service, documentation, and whether the scan is used in a qualifying diagnostic pathway (Centers for Medicare & Medicaid Services, 2013).
Anti-amyloid therapy has changed the reimbursement rationale. A PET scan can influence whether a patient is eligible for high-cost treatment, making the test clinically consequential. The reimbursement case remains sensitive to:
- The cost of PET imaging and radiotracer acquisition.
- Whether payers accept PET as sufficient evidence of amyloid pathology.
- Use of cerebrospinal fluid or blood-based testing instead.
- Coverage of repeat imaging for treatment monitoring.
- Hospital and physician interpretation fees.
- Regional availability of PET scanners and radiopharmacies.
The economics are stronger in integrated systems that control imaging, neurology, infusion, and radiopharmacy services. Independent imaging centers may face greater exposure to tracer supply and reimbursement variability.
What patents protect flutemetamol F-18?
The commercial protection profile for Vizamyl is less transparent than that of a conventional small-molecule prescription drug.
Flutemetamol F-18 is a diagnostic radiopharmaceutical based on a labeled imaging compound. Relevant intellectual property can include:
- The flutemetamol chemical entity.
- Fluorine-18 labeling and synthesis methods.
- Precursor compounds.
- Formulation and stability.
- Manufacturing and quality-control processes.
- Imaging methods and interpretation protocols.
- Commercial trademarks and regulatory exclusivity.
The key commercial barrier is manufacturing and distribution capability, not only compound patent life. A competitor must establish validated production, obtain regulatory authorization, meet radiopharmaceutical quality standards, and deliver doses within the usable time window.
The FDA Orange Book is the principal public source for listed patents and regulatory exclusivity associated with approved drug products. Diagnostic radiopharmaceutical listings and patent coverage may not provide a complete picture of all enforceable manufacturing, process, or foreign rights (FDA, 2024a). Public sources do not establish a single, reliable compound-patent expiration date that can be used as the sole predictor of Vizamyl competition.
Is Vizamyl exposed to generic or Paragraph IV competition?
There is no publicly established generic launch equivalent to a conventional oral drug challenge. A potential competitor could pursue an abbreviated or full application pathway depending on the product and regulatory framework, but it would still need to demonstrate pharmaceutical quality, imaging performance, manufacturing reliability, and site-specific distribution capability.
Paragraph IV litigation risk is therefore less visible than for high-revenue chronic medicines. The primary competitive threats are:
- Another approved amyloid PET tracer.
- Hospital-produced or regionally distributed alternatives.
- Blood-based biomarker adoption.
- Expansion of CSF testing.
- Regulatory approval of new diagnostic agents.
- Process or manufacturing competition after relevant intellectual property expires.
How strong is the Vizamyl patent estate?
The patent estate appears commercially meaningful but difficult to evaluate from public product-level disclosures alone.
Strengths
- Proprietary know-how in fluorine-18 labeling and production.
- GE HealthCare’s established radiopharmacy and imaging infrastructure.
- Regulatory experience in radiopharmaceutical manufacturing.
- Existing physician and hospital relationships.
- Operational barriers created by short product shelf life.
Weaknesses
- Multiple approved amyloid PET alternatives.
- Limited ability to differentiate on clinical outcome.
- Potential substitution by blood-based biomarkers.
- Limited publicly reported product economics.
- Dependence on reimbursement and PET capacity.
- Exposure to process and manufacturing competition.
The estate is stronger as an integrated commercial platform than as a standalone molecule protected only by composition-of-matter rights. Patent expiry would not automatically eliminate GE’s competitive position, but it could reduce pricing power if manufacturing and regulatory barriers become easier to overcome.
What licensing deals and collaborations affect Vizamyl?
GE HealthCare’s principal advantage is internal control over imaging technology, radiopharmaceutical production, and distribution. Public disclosures have not identified a major recent Vizamyl-specific licensing transaction that would materially alter the product’s economics.
The market includes broader collaborations involving:
- PET imaging centers.
- Alzheimer’s treatment networks.
- Radiopharmacy distributors.
- Diagnostic laboratories.
- Drug developers conducting clinical trials.
- Health systems building anti-amyloid treatment pathways.
Vizamyl may benefit indirectly from GE HealthCare’s broader relationships in molecular imaging, but company-level collaborations should not be treated as Vizamyl-specific revenue commitments without a product disclosure.
What litigation affects flutemetamol F-18?
No major publicly established patent litigation materially threatening Vizamyl’s U.S. commercial position is identified in the core FDA and company materials reviewed for this analysis.
Litigation risk is more likely to arise around:
- Patent claims covering tracer synthesis.
- Manufacturing and precursor technology.
- Regulatory approval of competing tracers.
- Distribution contracts.
- Reimbursement disputes.
- Product liability or interpretation claims.
The absence of a major disclosed dispute supports a relatively stable operating profile, but it does not eliminate future process-patent or market-entry litigation.
How does Vizamyl compare with Amyvid and Neuraceq?
| Factor |
Vizamyl |
Amyvid |
Neuraceq |
| Active tracer |
Flutemetamol F-18 |
Florbetapir F-18 |
Florbetaben F-18 |
| FDA approval order |
Second |
First |
Third |
| Primary market |
Amyloid PET |
Amyloid PET |
Amyloid PET |
| Key commercial advantage |
GE imaging and radiopharmacy platform |
Early market entry and brand recognition |
Alternative tracer and imaging option |
| Main constraint |
Reimbursement and competing biomarkers |
Same |
Same |
| Biosimilar risk |
None |
None |
None |
| Shelf-life and logistics exposure |
High |
High |
High |
| Product-level public revenue |
Not separately disclosed |
Not separately disclosed |
Not separately disclosed |
No tracer has a permanent monopoly because all three address the same diagnostic question. Local availability and payer acceptance can be more important than national brand share.
What generic launch scenarios exist for Vizamyl?
Base case: gradual growth
Vizamyl remains an established amyloid PET option. Volumes rise with Alzheimer’s treatment diagnosis, while pricing remains competitive. GE benefits from radiopharmacy scale and hospital relationships.
Upside case: PET-led treatment qualification
More clinicians use PET to qualify patients for lecanemab, donanemab, and future anti-amyloid therapies. Payers broaden coverage, and PET capacity expands. Vizamyl captures part of the incremental scan volume.
Downside case: blood-test substitution
Validated blood-based biomarkers become widely reimbursed and accepted for treatment eligibility. PET is reserved for equivocal cases, lowering the number of scans and limiting tracer growth.
Competitive-entry case: lower-cost tracer supply
A new producer or existing competitor offers reliable regional supply at lower prices. Vizamyl retains volume but faces margin pressure.
What geographic markets offer the strongest growth?
The United States has the strongest near-term opportunity because of its large Alzheimer’s treatment market, FDA-approved anti-amyloid therapies, and established PET infrastructure. Growth depends on Medicare coverage and health-system implementation.
Europe has significant diagnostic potential, but adoption is moderated by national reimbursement systems, slower drug launches, and uneven PET access. Japan and other developed Asian markets have relevant aging populations but require local regulatory approvals, reimbursement decisions, and radiopharmaceutical distribution networks.
Emerging markets have lower near-term commercial potential because PET scanners, radiopharmacies, and specialist neurology services are less widely available.
Key Takeaways
- Vizamyl is GE HealthCare’s FDA-approved flutemetamol F-18 amyloid PET tracer.
- The product was approved in 2013 and is used as an adjunct in evaluating adults with cognitive impairment.
- GE HealthCare does not disclose Vizamyl-specific revenue, profit, or unit volume.
- The commercial market is expanding because anti-amyloid therapies require confirmed amyloid pathology.
- Amyvid and Neuraceq are the principal direct competitors.
- Blood-based biomarkers are the largest long-term substitution risk.
- Radiopharmacy manufacturing, PET access, reimbursement, and distribution are as important as patent protection.
- No biosimilar pathway applies, and no major public Paragraph IV event is established.
- The most likely financial trajectory is gradual growth with meaningful upside from Alzheimer’s treatment qualification and downside from blood-test adoption.
- Product-level investment analysis requires company-segment data because standalone Vizamyl financial disclosures are unavailable.
FAQs About Flutemetamol F-18
Is Vizamyl the same as flutemetamol F-18?
Yes. Vizamyl is the brand name for flutemetamol F-18 injection, an amyloid PET radiopharmaceutical marketed by GE HealthCare.
Does Vizamyl treat Alzheimer’s disease?
No. Vizamyl is diagnostic. It estimates amyloid plaque density and does not slow or treat Alzheimer’s disease.
Can Vizamyl be used to qualify patients for Leqembi or Kisunla?
It can provide evidence of amyloid pathology, which is required in the labeled treatment pathways for lecanemab and donanemab. The final testing and treatment decision depends on the applicable FDA label, clinical judgment, and payer policy.
Is flutemetamol F-18 a biologic or biosimilar product?
No. It is a fluorine-18-labeled diagnostic small molecule. Biosimilar regulation does not apply.
What is the biggest commercial risk to Vizamyl?
The largest long-term risk is substitution by accurate, reimbursed blood-based Alzheimer’s biomarkers. Near-term risks are reimbursement restrictions, PET capacity limits, and competition from Amyvid and Neuraceq.
References
-
Centers for Medicare & Medicaid Services. (2013). Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease.
-
Food and Drug Administration. (2013). Vizamyl (flutemetamol F 18 injection) prescribing information.
-
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
Food and Drug Administration. (2024b). FDA approves treatment for adults with Alzheimer’s disease. Information on donanemab approval and amyloid pathology requirements.
-
Food and Drug Administration. (2023). FDA converts novel Alzheimer’s disease treatment to traditional approval. Information on lecanemab approval and amyloid confirmation requirements.
-
GE HealthCare Technologies Inc. (2024). Annual report for fiscal year 2023.
-
U.S. Food and Drug Administration. (2012). Amyvid (florbetapir F 18 injection) prescribing information.
-
U.S. Food and Drug Administration. (2014). Neuraceq (florbetaben F 18 injection) prescribing information.
